Emmaus Medical to Present at 6th Annual OneMedForum
TORRANCE, Calif., Dec. 19, 2012 /PRNewswire/ -- Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced that Peter Ludlum , the company's executive vice president and CFO, will give an overview of the company's Phase 3 sickle cell disease trial and discuss recent developments with its regenerative medicine research at the 6th Annual OneMedForum on January 8, 2013 at 9:50 a.m. P.T. at the Sir Francis Drake Hotel in San Francisco. Additionally, Yutaka Niihara , M.D., MPH, president and CEO, and Willis Lee , chief operating officer, will join Ludlum for one-on-one meetings throughout the day.
About Emmaus Medical, Inc.
Founded in 2000, Emmaus Medical, Inc. is a specialty pharmaceutical company, and subsidiary of Emmaus Life Sciences, Inc., dedicated to the discovery, development and commercialization of innovative and cost-effective treatments and therapies for rare diseases. The company is completing its Phase 3 clinical trial for a treatment for sickle cell disease and has entered into a collaborative agreement for the research, development and commercialization of regenerative medicine products. For more information, please visit www.emmausmedical.com and www.nutrestore.com.
SOURCE Emmaus Medical, Inc.
More by this Source
Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
May 09, 2013, 08:00 ET
Emmaus Medical Announces Completion of Enrollment for its Phase 3 Sickle Cell Disease Trial
Dec 03, 2012, 08:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.